RESUMO
Antiplatelet drugs are widely used in primary and secondary prevention of vascular embolism diseases, which can reduce the occurrence of cardiovascular and cerebrovascular adverse events. However, while inhibiting platelet aggregation, dual antiplatelet drugs can also affect the repair of gastrointestinal mucosa, leading to gastric ulcer formation and bleeding. More severely, patients may die from hemorrhage. The risk of severe hemorrhage increases significantly following a combination antiplatelet drug regimen. Endoscopic hemostasis should be the first choice for patients with gastrointestinal hemorrhage caused by dual antiplatelet therapy. Benefits and risks should be balanced. In order to prevent gastrointestinal mucosal injury caused by dual antiplatelet therapy, standardized process should be adopted to assess and screen the risk of patients, and the indications of antiplatelet therapy should also be standardized. Meanwhile,high-risk population of gastrointestinal injury should be identified in advance. In order to minimize the occurrence of gastrointestinal injury and bleeding, appropriate protective measures should be taken.